|
1
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rivera GK, Zhou Y, Hancock ML, et al: Bone
marrow recurrence after initial intensive treatment for childhood
acute lymphoblastic leukemia. Cancer. 103:368–376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fielding AK, Richards SM, Chopra R, et al:
Outcome of 609 adults after relapse of acute lymphoblastic leukemia
(ALL); an MRC UKALL12/ECOG 2993 study. Blood. 109:944–950. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas X, Boiron JM, Huguet F, et al:
Outcome of treatment in adults with acute lymphoblastic leukemia:
analysis of the LALA-94 trial. J Clin Oncol. 22:4075–4086. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marjerrison S, Antillon F, Fu L, et al:
Outcome of children treated for relapsed acute lymphoblastic
leukemia in Central America. Cancer. 119:1277–1283. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oriol A, Vives S, Hernández-Rivas JM, et
al: Outcome after relapse of acute lymphoblastic leukemia in adult
patients included in four consecutive risk-adapted trials by the
PETHEMA Study Group. Haematologica. 95:589–596. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang JH, Nichogiannopoulou A, Wu L, et al:
Selective defects in the development of the fetal and adult
lymphoid system in mice with an Ikaros null mutation. Immunity.
5:537–549. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Winandy S, Wu P and Georgopoulos K: A
dominant mutation in the Ikaros gene leads to rapid
development of leukemia and lymphoma. Cell. 83:289–299. 1995.
|
|
9
|
Rebollo A and Schmitt C: Ikaros, Aiolos
and Helios: transcription regulators and lymphoid malignancies.
Immunol Cell Biol. 81:171–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mullighan CG, Miller CB, Radtke I, et al:
BCR-ABL1 lymphoblastic leukaemia is characterized by the
deletion of Ikaros. Nature. 453:110–114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iacobucci I, Lonetti A, Cilloni D, et al:
Identification of different Ikaros cDNA transcripts in
Philadelphia-positive adult acute lymphoblastic leukemia by a
high-throughput capillary electrophoresis sizing method.
Haematologica. 93:1814–1821. 2008. View Article : Google Scholar
|
|
12
|
Koipally J and Georgopoulos K: A molecular
dissection of the repression circuitry of Ikaros. J Biol Chem.
277:27697–27705. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mullighan CG, Su X, Zhang J, et al:
Deletion of IKZF1 and prognosis in acute lymphoblastic
leukemia. N Engl J Med. 360:470–480. 2009.PubMed/NCBI
|
|
14
|
Tonnelle C, Imbert MC, Sainty D, Granjeaud
S, N’Guyen C and Chabannon C: Overexpression of dominant-negative
Ikaros 6 protein is restricted to a subset of B common adult acute
lymphoblastic leukemias that express high levels of the CD34
antigen. Hematol J. 4:104–109. 2003. View Article : Google Scholar
|
|
15
|
Zhou F, Mei H, Jin R, Li X and Chen X:
Expression of Ikaros isoform 6 in Chinese children with acute
lymphoblastic leukemia. J Pediatr Hematol Oncol. 33:429–432. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mi JQ, Wang X, Yao Y, et al: Newly
diagnosed acute lymphoblastic leukemia in China (II): prognosis
related to genetic abnormalities in a series of 1091 cases.
Leukemia. 26:1507–1516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harrison CJ: Cytogenetics of paediatric
and adolescent acute lymphoblastic leukaemia. Br J Haematol.
144:147–156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szczepański T, Harrison CJ and van Dongen
JJ: Genetic aberrations in paediatric acute leukaemias and
implications for management of patients. Lancet Oncol. 11:880–889.
2010.PubMed/NCBI
|
|
19
|
Mizuta S, Matsuo K, Yagasaki F, et al:
Pre-transplant imatinib-based therapy improves the outcome of
allogeneic hematopoietic stem cell transplantation for
BCR-ABL-positive acute lymphoblastic leukemia. Leukemia.
25:41–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wassmann B, Pfeifer H, Goekbuget N, et al:
Alternating versus concurrent schedules of imatinib and
chemotherapy as front-line therapy for Philadelphia-positive acute
lymphoblastic leukemia (Ph+ALL). Blood. 108:1469–1477.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ezzat S, Zhu X, Loeper S, Fischer S and
Asa SL: Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to
up-regulate a survival signal in pituitary cells. Mol Endocrinol.
20:2976–2986. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki K, Ono R, Ohishi K, et al: IKAROS
isoform 6 enhances BCR-ABL1-mediated proliferation of human
CD34+ hematopoietic cells on stromal cells. Int J Oncol.
40:53–62. 2012.PubMed/NCBI
|
|
23
|
Song JH, Kim SH, Cho D, Lee IK, Kim HJ and
Kim TS: Enhanced invasiveness of drug-resistant acute myeloid
leukemia cells through increased expression of matrix
metalloproteinase-2. Int J Cancer. 125:1074–1081. 2009. View Article : Google Scholar
|
|
24
|
Suminoe A, Matsuzaki A, Hattori H, Koga Y,
Ishii E and Harav T: Expression of matrix metalloproteinase (MMP)
and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute
lymphoblastic leukemia with organ involvement. Leuk Res.
31:1437–1440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaddu S, Zenahlik P, Beham-Schmid C, Kerl
H and Cerroni L: Specific cutaneous infiltrates in patients with
myelogenous leukemia: a clinicopathologic study of 26 patients with
assessment of diagnostic criteria. J Am Acad Dermatol. 40:966–978.
1999. View Article : Google Scholar : PubMed/NCBI
|
